Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could ...

Pterygium thickness did not meaningfully correlate with keratometry, astigmatism, irregularity indices, or most HOA metrics, suggesting depth contributes less to optical degradation than planar extent ...

Quantified preferences favored higher lesion growth rate reduction (10%→50% at 18 months) as the primary driver across all ...

Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm ...

An offline, point-of-care algorithm on a smartphone fundus camera generated disease-specific outputs without cloud connectivity, addressing a major deployment barrier in low-resource screening ...

Memento Medicines, a privately held biotech developing biologic therapies for retinal disease, has launched with a $93 ...

4FRONT-1, the first 4D-150 wet AMD phase 3 trial, is being conducted in North America in treatment-naïve patients with an ...

To explore what the veligrotug approval means for patients and practice, Ophthalmology Times posed the same questions to several TED specialists, including the following: Raymond S. Douglas, MD, PhD, ...

FDA labeling covers active and chronic TED, addressing a major evidentiary gap left by prior IGF-1R inhibition programs that primarily enrolled active disease populations. Two pivotal phase 3 trials ...

Geographic atrophy can emerge during stable anti-VEGF regimens for bilateral wet AMD, requiring deliberate surveillance and patient counseling rather than “treat-and-forget” follow-up. Coordinating ...

Peripheral retinal lesions occurred in 54.4% of highly myopic pediatric eyes, were bilateral in 64.2%, and increased in prevalence and multiplicity with age and more negative spherical equivalent.